Concerta and Adderall are two Schedule II central nervous system stimulants prescribed for attention deficit hyperactivity disorder, built on different molecules. Concerta is methylphenidate hydrochloride in an extended-release tablet, and Adderall is a single-entity amphetamine product combining four amphetamine salts in a 3-to-1 ratio of dextro- to levo-amphetamine.
Both carry an identical FDA boxed warning for abuse, misuse, and addiction, which the Food and Drug Administration required across the entire prescription stimulant class in a Drug Safety Communication dated May 11, 2023. The differences that matter clinically are release mechanics, duration, and approved indication: Concerta is approved for attention deficit hyperactivity disorder in patients aged 6 to 65, while Adderall is approved for attention deficit hyperactivity disorder and for narcolepsy.
Neither product has a dose equivalent in the other, and dose selection belongs to the prescriber who has examined the patient.
What Is the Difference Between Concerta and Adderall?
Concerta and Adderall differ in active molecule, release mechanism, half-life, and approved indication, while sharing Schedule II status and an identical boxed warning. The Concerta prescribing information describes an osmotic extended-release tablet delivering racemic methylphenidate, and the Adderall prescribing information describes an immediate-release tablet delivering a fixed mixture of dextroamphetamine and amphetamine salts.
The table below sets the two products side by side on the attributes each FDA label reports, so the comparison rests on labeling rather than on impression.
| Attribute | Concerta | Adderall |
| Active ingredient | Methylphenidate hydrochloride, a racemic mixture of d- and l-isomers | Four amphetamine salts: dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate |
| Drug class | Methylphenidate-type CNS stimulant | Amphetamine-type CNS stimulant |
| Isomer ratio | Racemic; the d-isomer is more pharmacologically active | 3-to-1 d- to l-amphetamine |
| Release | Extended: 22 percent immediate, 78 percent released over 24 hours | Immediate release |
| Time to peak plasma concentration | Initial peak at about 1 hour, mean overall peak between 6 and 10 hours | About 3 hours after dosing |
| Elimination half-life | About 3.5 hours | 9.77 to 11 hours for d-amphetamine; 11.5 to 13.8 hours for l-amphetamine |
| Approved indications | Attention deficit hyperactivity disorder, ages 6 to 65 | Attention deficit hyperactivity disorder and narcolepsy; not recommended under 3 years for attention deficit hyperactivity disorder; not studied in the geriatric population |
| DEA schedule | Schedule II | Schedule II |
| Boxed warning | Abuse, misuse, and addiction | Abuse, misuse, and addiction |
One physical property of Concerta has no Adderall equivalent. The Concerta label directs that the tablet be swallowed whole and not chewed, divided, or crushed, because the osmotic shell governs release, and the label carries a warning about gastrointestinal obstruction in patients with gastrointestinal narrowing. Those release mechanics also explain the two products' different pharmacological signatures.
How Does Each Medication Work in the Brain?
Both medications block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of those monoamines into the extraneuronal space. The Concerta label states that methylphenidate blocks that reuptake, the Adderall label states that amphetamines are thought to, and both state that the mode of therapeutic action in attention deficit hyperactivity disorder is not known.
Two label-level distinctions sit underneath the shared mechanism. Amphetamine also inhibits monoamine oxidase, which is why the Adderall label contraindicates the product in patients taking a monoamine oxidase inhibitor or within 14 days of stopping one, citing an increased risk of hypertensive crisis, and the label counts linezolid and intravenous methylene blue among the monoamine oxidase inhibitors that trigger the contraindication. And amphetamine elimination depends on urinary pH: the Adderall label reports urinary recovery of amphetamine ranging from 1 percent to 75 percent depending on urinary pH, so drugs that change urinary pH alter how long amphetamine stays in the body. Methylphenidate has no comparable pH dependence, and Concerta's label records that metabolism proceeds primarily by de-esterification to a metabolite with little or no pharmacologic activity. Half-life and formulation together determine how long each product acts.
How Long Does Each Medication Last?
Concerta is taken once daily in the morning and produced improvements maintained through 12 hours after dosing in its pediatric trials, while Adderall's immediate-release tablet reaches peak plasma concentration at about 3 hours and is given in divided doses across the day. Concerta's clinical trials in children aged 6 to 12 measured those improvements in attention and behavior on the SKAMP laboratory school rating scale.
The half-life numbers appear to contradict that 12-hour result, and the formulation resolves the contradiction. Methylphenidate's half-life from Concerta is about 3.5 hours, far shorter than d-amphetamine's 9.77 to 11 hours, yet Concerta acts longer because the osmotic tablet keeps releasing drug: plasma concentrations reach an initial peak at about 1 hour, then climb gradually over the next 5 to 9 hours, with the mean overall peak falling between 6 and 10 hours. Adderall's duration comes from the molecule's own long half-life rather than from a delivery system, which is why the label describes additional doses at intervals through the day. Food changes neither product's performance materially, and the Concerta label reports no difference in pharmacokinetics or pharmacodynamic performance after a high-fat breakfast. Duration and indication are separate questions, and the indications diverge.
Which Conditions Is Each Medication Approved to Treat?
Adderall is approved for attention deficit hyperactivity disorder and for narcolepsy, while Concerta is approved for attention deficit hyperactivity disorder alone in patients aged 6 to 65 years. That single-indication difference is the clearest non-pharmacological distinction between the two products.
Age boundaries differ as well. Concerta is not recommended in children younger than 6 years, because the label records higher plasma exposure and a higher incidence of adverse reactions including weight loss at the same dosage, and Concerta is not indicated in patients older than 65. Adderall is not recommended for children under 3 years of age for attention deficit hyperactivity disorder, and the label states Adderall has not been studied in the geriatric population. Both labels direct prescribers to assess for cardiac disease and to evaluate for motor or verbal tics and Tourette's syndrome before starting treatment. The risk both labels emphasize above all others is the one printed in a black box.
Do Concerta and Adderall Carry the Same Addiction Risk?
Concerta and Adderall carry the same boxed warning language: each has a high potential for abuse and misuse, which leads to the development of a substance use disorder including addiction, and misuse or abuse results in overdose and death. Both labels state that the risk increases with higher doses or with unapproved routes of administration such as snorting or injection.
The identical wording is the result of a deliberate FDA action. In May 2023 the agency required updates that made boxed warning information consistent across the entire prescription stimulant class, covering methylphenidate products including Concerta and amphetamine products including Adderall, and the revised labels followed later that year, with Adderall's revised in October 2023 and Concerta's published on October 30, 2023. The agency's stated reason for the update names the supply route: most people who misuse prescription stimulants obtain them from family members or peers, and sharing the medication leads to substance use disorder in the person it is shared with. Both labels instruct prescribers to assess abuse risk before prescribing, to educate patients and families about proper storage and disposal, and to reassess risk and monitor for signs of misuse throughout treatment. Formulation modifies exposure without removing risk: 22 percent of Concerta's methylphenidate is available immediately, and human abuse potential studies compared supratherapeutic single doses of Concerta against immediate-release methylphenidate on Drug Liking and Abuse Potential measures. What misuse produces is documented in the same labels.
What Happens When a Person Misuses a Prescription Stimulant?
Prescription stimulant misuse produces tolerance, a withdrawal syndrome on abrupt discontinuation, and a cardiovascular overdose profile that includes fatal outcomes. The Adderall label states that the product produces tolerance, defined as a reduced response requiring a higher dose to achieve the effect once obtained at a lower dose.
Withdrawal follows a recognizable pattern. The Adderall label names 7 signs after abrupt discontinuation or dose reduction following prolonged stimulant use: dysphoric mood, depression, fatigue, vivid and unpleasant dreams, insomnia or hypersomnia, increased appetite, and psychomotor retardation or agitation.
Overdose is a cardiovascular and neurological emergency. The Adderall label lists tachyarrhythmias, hypertension or hypotension, vasospasm, myocardial infarction, aortic dissection, sudden cardiac death, and Takotsubo cardiomyopathy among the cardiovascular effects, and psychomotor agitation, confusion, hallucinations, serotonin syndrome, seizures, cerebral vascular accidents, and coma among the central nervous system effects, alongside life-threatening hyperthermia above 104 degrees Fahrenheit and rhabdomyolysis. Call 911 for a suspected stimulant overdose, and the Adderall label directs anyone managing one to contact Poison Help at 1-800-222-1222 or a medical toxicologist. The population involved is not small: 3.9 million people aged 12 or older, 1.4 percent, misused a prescription stimulant in the past year, per the 2024 National Survey on Drug Use and Health. What separates a person needing a medication adjustment from a person needing treatment is a clinical question with a clinical answer.
How Is Prescription Stimulant Addiction Treated?
Prescription stimulant addiction is treated with behavioral therapy, because no medication is FDA-approved to treat stimulant use disorder. NIDA identifies cognitive behavioral therapy and contingency management as the behavioral approaches with evidence in stimulant use disorder, and psychiatric evaluation addresses the attention deficit hyperactivity disorder or mood condition underneath.
The clinical complication specific to stimulants is that a meaningful minority of misuse occurs in people who hold a legitimate prescription and diagnosis. FDA's review of the literature from January 2006 to May 2020 attributed 10 to 20 percent of past-year nonmedical stimulant use to the person's own prescription, against 56 to 80 percent obtained from friends or family, so treatment has to separate the disorder being treated from the pattern of use that developed around it. Valley Spring Recovery Center provides outpatient Adderall addiction treatment in Norwood, Bergen County, NJ, with psychiatric evaluation delivered by the medical director and a psychiatric nurse practitioner, so both questions are addressed in one plan. Admissions staff at (855) 924-5320 complete a free, confidential pre-assessment at any hour. Readers researching this comparison for a prescribing decision will find the clinical evidence in the guide to Adderall for ADHD, readers looking at use without a diagnosis will find the effects set out in what Adderall does to a normal person, and the full symptom and treatment picture for Adderall addiction sits in the parent guide.
What Are the Most Common Questions About Concerta and Adderall?
The 6 questions below cover strength comparisons, duration, interchangeability, and addiction facts people search most about Concerta and Adderall. Each answer stands alone in 40 words or fewer.
Is Concerta Stronger Than Adderall?
Neither is stronger. Neither product's FDA labeling provides a conversion between methylphenidate and amphetamine, so no equivalence ratio exists between them. Concerta releases methylphenidate over 24 hours; Adderall releases amphetamine salts immediately.
Which Lasts Longer, Concerta or Adderall?
Concerta is taken once daily in the morning, and its pediatric trials measured improvements maintained through 12 hours after dosing. Immediate-release Adderall peaks at about 3 hours and is given in divided doses.
Can You Switch From Concerta to Adderall?
Switching between methylphenidate and amphetamine products is a prescriber decision, because the molecules differ and neither product's FDA labeling provides a dose conversion between methylphenidate and amphetamine.
Is Concerta Less Addictive Than Adderall?
No. Both carry the same FDA boxed warning for abuse, misuse, and addiction, required across the prescription stimulant class in May 2023. Extended release modifies exposure without removing abuse potential.
Are Concerta and Adderall Both Controlled Substances?
Yes. Concerta contains methylphenidate and Adderall contains amphetamine, and both are Schedule II controlled substances under federal law, per each product's FDA prescribing information.
What Are the Withdrawal Symptoms From Stimulants?
The Adderall label names dysphoric mood, depression, fatigue, vivid unpleasant dreams, insomnia or hypersomnia, increased appetite, and psychomotor retardation or agitation after abrupt discontinuation or dose reduction following prolonged use.